Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI, with panobinostat, a HDACi, to determine the maxi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood Cancer J
Autors principals: Kaufman, Jonathan L., Mina, Roberto, Jakubowiak, Andrzej J., Zimmerman, Todd L., Wolf, Jeffrey J., Lewis, Colleen, Gleason, Charise, Sharp, Cathy, Martin, Thomas, Heffner, Leonard T., Nooka, Ajay K., Harvey, R. Donald, Lonial, Sagar
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6320362/
https://ncbi.nlm.nih.gov/pubmed/30610196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0154-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars